FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2758338506> ?p ?o ?g. }

• W2758338506 endingPage "3019" @default.
• W2758338506 startingPage "3019" @default.
• W2758338506 abstract "Background: PARP-1 is a nuclear enzyme that signals DNA strand breaks for repair. There is considerable interest in PARP-1 in health and disease and the development of PARP inhibitors for cancer therapy. A number of PARP inhibitors have now entered clinical trials. We report here the development of sensitive assays for both PARP-1 protein and activity, validated to GCLP, that are applicable to pre-clinical and clinical samples that may be used to guide pre-clinical development of PARP inhibitors and evaluation of their activity in clinical trials. Methods: We determined PARP-1 protein expression and activity in fresh cultured cells or human lymphocytes or following freezing in culture medium supplemented with 10% DMSO and protease inhibitors. PARP-1 protein was measured by semi-quantitative Western blot using anti PARP-1 C2-10 primary and polyclonal Goat antimouse secondary antibody (Ab) by reference to 40-2.5ng PARP-1 protein standard curve and K562 cell lysates as QC samples. Maximum stimulatable PARP activity was determined following incubation of permeabilised cells with NAD and 30-mer oligonucleotide by immunological detection of ADP-ribose polymers (PAR) (1) following blotting on to hybond-N membrane using a purpose-built (PE 300: Polyethylene) manifold with 12mm radii wells using 10H primary and a Goat anti-mouse secondary Ab by reference to a PAR standard curve and cultured cell QC samples. Both protein and activity was quantified by ECL chemiluminescence. Results: The limit of detection of PARP-1 protein and PARP-1 activity was 2.5 ng and 0.02 pmol, respectively. Inter assay variability was 40 % coefficient of variation (CV) for protein and 25% CV for activity but intra assay variability was below 15% CV for both assays. For this reason we recommend that all samples from one patient are run in the same assay. PARP activity could be detected in as few as 5000 cultured human cancer cells and 10 000 human lymphocytes and only 30µg soluble protein extract from cultured cells and human lymphocytes were needed to measure PARP-1 protein levels. Thus both protein and activity could be measured in triplicate samples in 2 independent assays with only 10 ml blood. PARP activity, and its inhibition by AG014699, was maintained for at least 14 weeks at -80 o C. This assay has been used as a secondary endpoint in clinical trials of the Pfizer PARP inhibitor AG-014699. Conclusions: Determination of PARP activity and expression can be determined in cultured cells and patient lymphocytes. Rigorous guidelines for the preparation of samples alongside standards and quality controls provide a robust and highly sensitive assay for evaluation of novel PARP inhibitors pre-clinically and clinically. 1-Plummer ER et al Clinical Cancer Research. 11 3402-3409 (2005) Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 3019." @default.
• W2758338506 created "2017-10-06" @default.
• W2758338506 creator A5001447451 @default.
• W2758338506 creator A5015442135 @default.
• W2758338506 creator A5033962986 @default.
• W2758338506 creator A5060573126 @default.
• W2758338506 creator A5075175688 @default.
• W2758338506 creator A5082238212 @default.
• W2758338506 date "2009-05-01" @default.
• W2758338506 modified "2023-10-17" @default.
• W2758338506 title "Abstract #3019: Validated sensitive immunological determination of PARP-1 protein levels and activity in cultured cells and human lymphocytes" @default.
• W2758338506 hasPublicationYear "2009" @default.
• W2758338506 type Work @default.
• W2758338506 sameAs 2758338506 @default.
• W2758338506 citedByCount "0" @default.
• W2758338506 crossrefType "journal-article" @default.
• W2758338506 hasAuthorship W2758338506A5001447451 @default.
• W2758338506 hasAuthorship W2758338506A5015442135 @default.
• W2758338506 hasAuthorship W2758338506A5033962986 @default.
• W2758338506 hasAuthorship W2758338506A5060573126 @default.
• W2758338506 hasAuthorship W2758338506A5075175688 @default.
• W2758338506 hasAuthorship W2758338506A5082238212 @default.
• W2758338506 hasConcept C104317684 @default.
• W2758338506 hasConcept C153911025 @default.
• W2758338506 hasConcept C159654299 @default.
• W2758338506 hasConcept C181199279 @default.
• W2758338506 hasConcept C182979987 @default.
• W2758338506 hasConcept C185592680 @default.
• W2758338506 hasConcept C203014093 @default.
• W2758338506 hasConcept C2776415932 @default.
• W2758338506 hasConcept C2779138821 @default.
• W2758338506 hasConcept C55493867 @default.
• W2758338506 hasConcept C71924100 @default.
• W2758338506 hasConcept C82381507 @default.
• W2758338506 hasConcept C85265743 @default.
• W2758338506 hasConcept C86803240 @default.
• W2758338506 hasConcept C956191 @default.
• W2758338506 hasConceptScore W2758338506C104317684 @default.
• W2758338506 hasConceptScore W2758338506C153911025 @default.
• W2758338506 hasConceptScore W2758338506C159654299 @default.
• W2758338506 hasConceptScore W2758338506C181199279 @default.
• W2758338506 hasConceptScore W2758338506C182979987 @default.
• W2758338506 hasConceptScore W2758338506C185592680 @default.
• W2758338506 hasConceptScore W2758338506C203014093 @default.
• W2758338506 hasConceptScore W2758338506C2776415932 @default.
• W2758338506 hasConceptScore W2758338506C2779138821 @default.
• W2758338506 hasConceptScore W2758338506C55493867 @default.
• W2758338506 hasConceptScore W2758338506C71924100 @default.
• W2758338506 hasConceptScore W2758338506C82381507 @default.
• W2758338506 hasConceptScore W2758338506C85265743 @default.
• W2758338506 hasConceptScore W2758338506C86803240 @default.
• W2758338506 hasConceptScore W2758338506C956191 @default.
• W2758338506 hasLocation W27583385061 @default.
• W2758338506 hasOpenAccess W2758338506 @default.
• W2758338506 hasPrimaryLocation W27583385061 @default.
• W2758338506 hasRelatedWork W1942021132 @default.
• W2758338506 hasRelatedWork W1964503491 @default.
• W2758338506 hasRelatedWork W1964967988 @default.
• W2758338506 hasRelatedWork W1993902592 @default.
• W2758338506 hasRelatedWork W1994356726 @default.
• W2758338506 hasRelatedWork W2020050605 @default.
• W2758338506 hasRelatedWork W2025843504 @default.
• W2758338506 hasRelatedWork W2031867868 @default.
• W2758338506 hasRelatedWork W2055386134 @default.
• W2758338506 hasRelatedWork W2057264887 @default.
• W2758338506 hasRelatedWork W2074064462 @default.
• W2758338506 hasRelatedWork W2119727971 @default.
• W2758338506 hasRelatedWork W2146678563 @default.
• W2758338506 hasRelatedWork W2171883353 @default.
• W2758338506 hasRelatedWork W2257816848 @default.
• W2758338506 hasRelatedWork W2463615417 @default.
• W2758338506 hasRelatedWork W2791849065 @default.
• W2758338506 hasRelatedWork W2810758929 @default.
• W2758338506 hasRelatedWork W3119614833 @default.
• W2758338506 hasRelatedWork W650398648 @default.
• W2758338506 hasVolume "69" @default.
• W2758338506 isParatext "false" @default.
• W2758338506 isRetracted "false" @default.
• W2758338506 magId "2758338506" @default.
• W2758338506 workType "article" @default.